Scott Seidelmann - Omnicell President
| OMCL Stock | USD 46.90 0.71 1.49% |
President
Mr. Scott P. Seidelmann is Executive Vice President and Chief Commercial Officer of the company. Prior to joining Omnicell, from January 2015 to August 2017, Mr. Seidelmann served as founder and Chief Executive Officer of Candescent Health, Inc., a cloudbased radiology workflow and analytics provider. From 2005 to 2014, Mr. Seidelmann served as cofounder and Chief Executive Officer of Radisphere, Inc., a national radiology practice, prior to its acquisition by Sheridan Healthcare. Earlier in his career, Mr. Seidelmann held positions with Merrill Lynch and Ericsson Venture Partners since 2018.
| Age | 48 |
| Tenure | 6 years |
| Address | 4220 North Freeway, Fort Worth, TX, United States, 76137 |
| Phone | 877 415 9990 |
| Web | https://www.omnicell.com |
Omnicell Management Efficiency
Return On Tangible Assets is expected to rise to -0.02 this year. Return On Capital Employed is expected to rise to -0.02 this year. At this time, Omnicell's Intangible Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 297.7 M this year, although the value of Return On Tangible Assets are projected to rise to (0.02). Omnicell's management efficiency ratios could be used to measure how well Omnicell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| Nicholas McGrane | Evolent Health | 49 | |
| Edward Pearson | HealthStream | 61 | |
| Patrick PharmD | Certara | 53 | |
| Leif Pedersen | Certara | 60 | |
| Michael Sousa | HealthStream | 55 | |
| Robert Aspbury | Certara | 52 | |
| Mollie Condra | HealthStream | N/A | |
| Michael Collier | HealthStream | 48 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Trisha Coady | HealthStream | 48 | |
| Jeffrey Cunningham | HealthStream | 57 | |
Management Performance
| Return On Equity | -0.0146 | ||||
| Return On Asset | -0.0087 |
Omnicell Leadership Team
Elected by the shareholders, the Omnicell's board of directors comprises two types of representatives: Omnicell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omnicell. The board's role is to monitor Omnicell's management team and ensure that shareholders' interests are well served. Omnicell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omnicell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Spears, Principal Chief Accounting Officer | ||
| Kathleen Nemeth, Senior Relations | ||
| Vicki MacDevitt, Chief Staff | ||
| Sara Dalmasso, Senior International | ||
| Jorge Taborga, Executive Vice President - Engineering | ||
| Minoo Mortazavi, Senior Operations | ||
| Corey Manley, Executive Officer | ||
| David Vanella, Senior Regulatory | ||
| Roxanne Turner, Sr Officer | ||
| Nchacha Etta, Executive CFO | ||
| Randall Lipps, Executive Chairman, CEO and Pres | ||
| Scott Seidelmann, Executive Vice President and Chief Commercial Officer | ||
| Nnamdi Njoku, Executive COO | ||
| Christine Mellon, Chief VP | ||
| Peter Kuipers, CFO, Executive Vice President | ||
| Brian Nutt, Chief VP | ||
| Maximo Rocha, Senior Officer | ||
| Giri Chodavarapu, Senior Officer |
Omnicell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omnicell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0146 | ||||
| Return On Asset | -0.0087 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 2.24 B | ||||
| Shares Outstanding | 46.32 M | ||||
| Shares Owned By Insiders | 1.67 % | ||||
| Shares Owned By Institutions | 98.33 % | ||||
| Number Of Shares Shorted | 1.36 M | ||||
| Price To Earning | 64.95 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.558 | Earnings Share (0.39) | Revenue Per Share 23.218 | Quarterly Revenue Growth (0.05) | Return On Assets (0.01) |
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.